JEITO CAPITAL becomes key investor in NMD Pharma as part of a €35 Million new financing

• Jeito Capital selected European clinical stage biotech NMD Pharma, based in Denmark, as its 7th investment and leads the new financing
  
• Proceeds will be used to progress clinical lead programs, expand the number of target indications, and enlarge R&D capabilities in severe neuromuscular disorders

Paris, France, February 2022, 15th – Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, today announces that it has become a key investor as part of a €35 Million new financing round in NMD Pharma. The Danish biotech company is developing breakthrough therapies for patients suffering from severe neuromuscular disorders.

Jeito Capital is leading this new round of financing with investments from current NMD Pharma investors INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck Foundation.  Jeito Capital is joining the NMD Pharma Board with the appointment of Sabine Dandiguian, Managing Partner, as Non-Executive Director.

The new financing will enable NMD Pharma to expand its clinical programs to several neuromuscular diseases including spinal muscular atrophy. It will further enable the company to grow the pipeline and support expansion to new targets in severe neuromuscular diseases. NMD Pharma has built a strong platform and a high level of expertise specifically dedicated to neuromuscular field. This new financing is another step towards deploying to multiple severe patient populations to fully leverage these capabilities.

With NMD Pharma, Jeito is diversifying and strengthening its portfolio with a clinical stage company in a new area of research in accordance with its strategic investment roadmap. Jeito will continue supporting the company in refining its market entry strategy, bringing its strong expertise to accelerate this potential groundbreaking therapy towards patients.

Rafaèle Tordjman, Founder & CEO of Jeito Capital said: “Jeito Capital has built over the two last years a diversified portfolio of the next generation of European biotech leaders with a global reach in different therapeutic areas and development stages. We are very proud to collaborate with a strong syndicate of investors including leading pharma players to bring new therapies to the patients suffering from severe neuromuscular disorders. I think that NMD Pharma is very illustrative of the maturing and high quality European Biotech ecosystem which Jeito wants to support in its growth to create market leaders addressing severe high unmet medical needs.”

Sabine Dandiguian, Managing Partner at Jeito Capital, added: “The knowledge and R&D process in the field of neuromuscular disorders is outstanding from the NMD Pharma management team. The potential of the pipeline is supported by compelling data, including for their lead candidate, NMD670 to treat symptoms of Myasthenia Gravis, a rare and chronic autoimmune disease. Jeito is proud to have contributed to this financing for NMD Pharma and I look forward to working with Thomas Holm Pedersen, the CEO and his team to help support the company’s growth as it enters an exciting time in its development. Jeito is committed to investing in and working closely with companies such as NMD Pharma that are developing breakthrough treatments for patients living with diseases with high unmet needs.”

Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: “The closing of this financing round is a testament to the clear vision and ambition of NMD Pharma to become a leader in the field of neuromuscular diseases. It reflects decades of scientific work in the area and the unique potential of our people for growing our development pipeline. Furthermore, we are intrigued with the broad clinical utility of our CLC-1 inhibitor portfolio and look forward to continuing our efforts to provide treatments for patients suffering from neuromuscular diseases. We are pleased to welcome Jeito Capital with Sabine Dandiguianto our Board. Her network of industry contacts and strategic business advice will be invaluable to us as we grow and expand our business.”

 ***

 CONTACTS

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access in Europe & the United States. Jeito Capital has €534 million under management. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit www.jeito.life, or follow on Twitter @Jeito_life or LinkedIn.

About NMD Pharma

NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in-vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received seed financing from Novo Seeds, Lundbeck Foundation and Capnova in 2016, and in 2018 raised a €38 million Series A financing, led by new investor INKEF Capital, together with new investor Roche Venture Fund and existing investors Novo Seeds and Lundbeck Foundation. Find out more about us online at http://www.nmdpharma.com/.